Robert W. Baird Analysts Give R1 RCM (NASDAQ:RCM) a $14.00 Price Target

Share on StockTwits

Robert W. Baird set a $14.00 price objective on R1 RCM (NASDAQ:RCM) in a report released on Thursday morning, TipRanks reports. The brokerage currently has a buy rating on the financial services provider’s stock.

RCM has been the topic of a number of other reports. BidaskClub downgraded shares of R1 RCM from a buy rating to a hold rating in a research report on Thursday. ValuEngine upgraded shares of R1 RCM from a buy rating to a strong-buy rating in a report on Wednesday, September 4th. Finally, Zacks Investment Research cut shares of R1 RCM from a buy rating to a hold rating in a report on Tuesday, August 13th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $14.20.

R1 RCM stock traded up $0.18 during mid-day trading on Thursday, reaching $10.68. 1,450,670 shares of the company traded hands, compared to its average volume of 841,567. The company has a debt-to-equity ratio of 106.30, a current ratio of 0.90 and a quick ratio of 0.90. The firm’s 50 day moving average price is $11.91 and its 200 day moving average price is $11.38. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -33.38 and a beta of 0.15. R1 RCM has a 52-week low of $7.10 and a 52-week high of $13.19.

R1 RCM (NASDAQ:RCM) last issued its quarterly earnings data on Tuesday, August 6th. The financial services provider reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($0.08). The company had revenue of $295.00 million for the quarter, compared to analysts’ expectations of $294.11 million. R1 RCM had a negative net margin of 2.22% and a negative return on equity of 249.01%. The firm’s revenue for the quarter was up 41.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.07) earnings per share. On average, sell-side analysts anticipate that R1 RCM will post -0.01 EPS for the current year.

Several hedge funds have recently made changes to their positions in the company. Swiss National Bank boosted its holdings in shares of R1 RCM by 2.1% during the 2nd quarter. Swiss National Bank now owns 164,100 shares of the financial services provider’s stock valued at $2,064,000 after buying an additional 3,400 shares in the last quarter. NumerixS Investment Technologies Inc boosted its holdings in shares of R1 RCM by 73.3% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 10,400 shares of the financial services provider’s stock valued at $131,000 after buying an additional 4,400 shares in the last quarter. Insight Wealth Strategies LLC boosted its holdings in shares of R1 RCM by 4.7% during the 2nd quarter. Insight Wealth Strategies LLC now owns 185,928 shares of the financial services provider’s stock valued at $2,339,000 after buying an additional 8,357 shares in the last quarter. Bank of Montreal Can boosted its holdings in shares of R1 RCM by 179.5% during the 2nd quarter. Bank of Montreal Can now owns 13,308 shares of the financial services provider’s stock valued at $168,000 after buying an additional 8,547 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of R1 RCM by 0.7% during the 2nd quarter. Northern Trust Corp now owns 1,283,606 shares of the financial services provider’s stock valued at $16,147,000 after buying an additional 8,568 shares in the last quarter. Hedge funds and other institutional investors own 70.91% of the company’s stock.

About R1 RCM

R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers.

Featured Article: If I purchase shares through a brokerage account, am I the holder of record?

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.